Obesity and Clozapine Use in Schizophrenia.
Schizophrenia (SZ) is a chronic mental disorder that affects about 1% of the world population,
and mainly happens in the end of adolescence and the beginning of adulthood, regardless of
gender or social groups. It is a disease characterized by distortions in thoughts, bizarre delusions and changes in sensory perception and inappropriate emotional responses that lead patients to some degree of deterioration.
Negative symptoms described were: apathy, loss of pleasures in activities once the provided, unwillingness to start a behavior directed at a goal and poverty of speech. As the positives symptoms are the level of mental disorders such as delusions, distortion of thoughts, unreal perceptions, such as audio-visual hallucinations, excessive anxiety, impulses and aggression.
Clozapine is a reference atypical antipsychotic, having distinct characteristics of the medications available before its release, which showed effective in 30% to 60% of psychoses that do not respond to traditional drugs, and low incidence of adverse effects, becoming the main indication for refractory schizophrenia. Atypical offer several important advantages over typical, including its characteristics of low risk of extrapyramidal symptoms such as akathisia, dystonia, parkinsonism and tardive dyskinesia, improved cognition, reduced suicide and minor depression compared with typical antipsychotics at clinically relevant doses.
Associated with pharmacological treatment, nutritional and psychological treatments are very important in the improvement of the condition of these patients. Obesity is a non transmissible chronic disease, which presents itself not only as a scientific problem, but also as a public health problem. The modern lifestyle with a more westernized diet, associated with a decrease in physical activity, converges to the increase in worldwide obesity.
Obes Res Open J. 2016; 3(2): 24-29.doi: 10.17140/OROJ-3-124